The tobacco endgame: where are we, and what are the challenges ahead?

Allan Brandt¹, Mateusz Zatoński²,³,⁴

¹Department of the History of Science, Harvard University, USA
²Health Promotion Foundation, Nadarzyn, Poland
³European Observatory of Health Inequalities, the President Stanisław Wojciechowski State University of Applied Sciences in Kalisz, Poland
⁴Department for Health, University of Bath, United Kingdom

ADDRESS FOR CORRESPONDENCE: Mateusz Zatoński, PhD, Health Promotion Foundation, 51 Mszczonowska St., 05-830 Nadarzyn, Poland, e-mail: zatonski.mateusz@gmail.com

Supplementary materials (slides) are available in Webappendix 4 at the journal’s website: https://www.termedia.pl/Journal/Journal_of_Health_Inequalities-100.

DOI: https://doi.org/10.5114/jhi.2019.87819

The first panel of the second day of the Calisia World Conference on Family Health, held in Kalisz, Poland on 9–10 June 2019, was devoted to one of the defining public health problems of the last century – cigarette smoking. The panel gathered a range of experts, representing fields ranging from economics, through history, to health advocacy, who attempted to summarise the current state of affairs in tobacco control and outline the key challenges ahead.

The panel opened with two presentations putting tobacco control efforts into a wider historical context. First, the audience watched Allan Brandt’s video address, in which he gave a broad introduction to the panel, looking at the history of tobacco control, and in particular of tobacco industry misconduct, in the last century. See the transcription of Allan Brandt’s presentation below, and the key points summarised in Box 1.

Allan Brandt’s video address:

It is wonderful to be here in Calisia with you today, even from this great distance, in this digital format. Many thanks to Mateusz Zatoński for his introduction and especially for including me in this important panel. And I especially want to acknowledge the visionary work of Dr. Witold Zatoński, one of the truly great, historic leaders of public health in the 20th and 21st centuries, whose work has saved lives and preserved the health of millions of people here in Poland, in Europe, and across the globe. All of us who are dedicated to reducing suffering and to preserving good health are in his debt, and this conference clearly indicates the impact that he has had.

My brief remarks this morning are based significantly on my collaboration with Mateusz Zatoński, and I thought this might be a useful occasion to briefly reflect historically as we consider the foundation for critical next steps in tobacco control. My orientation to this stems from the organisation and implementation in the middle of the 20th century of what has widely come to be called the tobacco industry playbook. This strategy emphasised aggressive work on the part of the companies to undermine the science that had demonstrated the harms of tobacco. It did this through industry-funded research by claiming that “the jury is still out”. It did it by promoting what they called safer products, even though there was no scientific or medical evidence that these products actually reduce the harms of smoking. It did it by aggressively promoting tobacco products to children, because they knew that the youth market would be crucial to the continuation of their industry. And they did it...
by aggressively promoting the notion of *individual choice* and especially *individual responsibility*. They intensively resisted product regulation and public health measures and worked through their deep pockets to lobby aggressively in both public and political realms to undermine all forms of successful public health intervention.

This playbook was exposed by exceptional science, public health, legal reform, and policy, but it’s striking that these strategies continue to be utilised. Today we understand that these approaches have been embraced by many other global industries, since its original design and implementation by Big Tobacco in the 1950s and 1960s. Today we see this in the food and beverage industries and many other companies that produce harmful products. In these ways, industries continue to contribute enormously to the health disparities that this conference seeks to address and reduce. Despite the power and effectiveness of this playbook, public health forces, under the leadership of people like Dr. Zatoński, have made remarkable progress against smoking and its myriad harms over the last half century.

Despite these accomplishments, powerful industrial interests continue to create important challenges to public health and health equality. I want to emphasise that at this particular historical moment we’re in an especially complex situation as we examine the future of tobacco control and the impact of nicotine addiction. This is a remarkable inflection point as we consider the future of tobacco control and the impact of nicotine addiction. This is a complex situation as we examine the future of tobacco control and the impact of nicotine addiction.

Harm reduction is an especially appealing approach to combustible tobacco products, but as the tobacco industry well understands, it is dividing the public health experts and advocates. The term *harm reduction* is ambiguous, and its evaluation and measurement and implementation is far from clear. How much harm reduction do we need to demonstrate to endorse and promote a new product? A little harm reduction? Just any harm reduction? Considerable harm reduction? Harm reduction for some, perhaps adults, can, for example, lead to significant new harms among children and teenagers. How are we to balance the overall impact on health of a new product as we consider appealing notions like harm reduction? How might we consider *harm production* by e-cigarettes versus the potential of *harm reduction*?

There are significant efforts instigated by the industry itself to resist the regulation of e-cigarettes, their promotion, and their use. But in the long term, the longitudinal impact of these new products is threatening and potentially far from clear. We know that public health can be dramatically improved, but, importantly, it can also be reduced as we’re seeing right now in the US with the current epidemic of measles, a disease that was virtually eradicated only 25 years ago. So, as we consider approaches to the tobacco “endgame”, we need to recognise the possibility that a complex market of vaping products as well as combustible tobacco products, could lead to more harm, morbidity, and mortality in the decades and even the century ahead. This regrettably would augment the critical health inequalities that the Calisia Declaration so effectively and humanely seeks to illuminate. Great vigilance and commitment to maintain and expand the successes of the last 50 years in tobacco control will be needed. I know that all of us here.

**Box 1. Key points we need to focus on as we consider the future of tobacco control globally**

1. A deep sense of the history of the rise of cigarette smoking and the emergence in the middle of the 20th century of the tobacco industry “playbook.” This strategy emphasised: undermining established science through industry funded research; claiming the “jury is still out”; promoting “safer” products; promoting to children; asserting individual choice and individual responsibility; intensively resisting both product regulation and public health measures; deep-pocketed political lobbying and public relations.

2. Although the playbook was exposed through exceptional science, public health, law, and policy, it remains active and has been embraced by many other global industries since its design and implementation by Big Tobacco. Today we see this in food, beverages, and many other industries that produce significantly harmful products.

3. In this way these industries contribute enormously to the health disparities that public health seeks to address and reduce.

4. Despite the power and effectiveness of the “playbook”, public health forces have made remarkable progress against smoking and its myriad harms over the last half century, saving millions of lives.

5. Despite these accomplishments, powerful business interests create important challenges of public health and health equality.

6. At this moment we are in a complex situation as we examine the future of tobacco control and the impact of nicotine addiction.

7. The introduction and aggressive marketing of e-cigarettes, and their promotion as “harm reduction”, has the potential to disrupt the remarkable progress made.

8. Harm reduction is a very appealing way to further reduction in the use of combustible tobacco products. But as the industry understood, it has divided the public health community. The very term “harm reduction” is ambiguous, and its evaluation and measurement are unclear. How much harm reduction?
A little? A lot? Harm reduction for some (i.e. adults) can, as we have seen, produce harm for others (children). How might we consider the “harm produced” by e-cigarettes vs. potential harm reduction.

9. There are considerable efforts to resist the regulation of e-cigarettes, their promotion, and their use.
10. We know that public health can be improved, but, importantly, we know it can be reduced (witness the current measles epidemic in the United States).

As we consider approaches to the “tobacco endgame” we will need to recognise that the possibility remains that a complex market of vaping products and combusting products could lead to more harm, morbidity, and mortality in the decades ahead.

11. This would augment the critical health inequalities that the Calisia Declaration illuminates [2].

today are committed to freeing the world of the harms of tobacco products and its associated addictions. So, it’s really a great pleasure to be included this morning.
I want to thank you very much and send my warmest wishes through the success of the work you’re doing there. Thank you very much.

DISCLOSURE
The authors report no conflict of interest.

References

AUTHOR’S CONTRIBUTIONS
AB prepared the text based on his video address at the Calisia Conference, as well as the text in Box 1. MZ wrote the introduction and conceptualised the contribution.